(RTTNews) - Johnson & Johnson (JNJ) said Thursday the U.S. Food and Drug Administration (FDA) granted accelerated approval to Rybrevant Faspro as a standalone treatment for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or af

J&J's Rybrevant Faspro Wins FDA Accelerated Approval For Advanced Head And Neck Cancer 

Key PointsEli Lilly’s impressive run looks likely to continue over the next few years.

2 Growth Stocks to Buy in November Without Any Hesitation

Key PointsThe Magnificent Seven make up about one-third of the S&P 500.

Worried About an AI Bubble? This ETF Could Be the Smartest Buy Right Now

Key PointsAbbVie survived its loss of Humira, and its profits are soaring.

The Best Dividend Stocks to Buy With $5,000 in November

(RTTNews) - Johnson & Johnson (JNJ) said Sunday its investigational Shockwave Javelin coronary intravascular lithotripsy (IVL) catheter exceeded both primary endpoint performance goals in the pivotal FORWARD CAD study. Separately, the company reported favorable outcomes from thre

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT 

Key PointsIntuitive Surgical is a leader in the surgical robotics space, with a huge installed base of its da Vinci robots.

Intuitive Surgical Stock Just Fell Despite a 22% Revenue Jump. Here's What Investors Are Missing.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson News